The FDA has reversed its initial refusal and will now review Moderna’s application for the first mRNA-based flu vaccine, targeting a completion date of August 5. The sudden reversal follows a week of intense criticism from the medical community, with many viewing the initial rejection as a sign of shifting vaccine policies under the current administration. In a meeting held by the FDA, Moderna successfully amended its regulatory approach. The development occurs amidst a tense political climate where Health Secretary Robert F. Kennedy Jr. has already canceled significant funding for mRNA research.
Date: February 18, 2026. Source: theguardian.com